Currently, there are 223.11M common shares owned by the public and among those 124.19M shares have been available to trade.
The company’s stock has a 5-day price change of -17.09% and 11.76% over the past three months. SANA shares are trading 39.88% year to date (YTD), with the 12-month market performance down to -74.81% lower. It has a 12-month low price of $1.52 and touched a high of $10.50 over the same period. SANA has an average intraday trading volume of 7.36 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -15.45%, -22.72%, and -43.85% respectively.
Institutional ownership of Sana Biotechnology Inc (NASDAQ: SANA) shares accounts for 55.96% of the company’s 223.11M shares outstanding.
It has a market capitalization of $509.05M and a beta (3y monthly) value of 1.55. The earnings-per-share (ttm) stands at -$1.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.73% over the week and 9.81% over the month.
Earnings per share for the fiscal year are expected to increase by 19.83%, and 4.12% over the next financial year. EPS should grow at an annualized rate of 3.95% over the next five years, compared to -83.13% over the past 5-year period.
Looking at the support for the SANA, a number of firms have released research notes about the stock. Citizens JMP stated their Mkt Outperform rating for the stock in a research note on March 18, 2025, with the firm’s price target at $5. Jefferies coverage for the Sana Biotechnology Inc (SANA) stock in a research note released on March 14, 2025 offered a Buy rating with a price target of $7. Rodman & Renshaw on their part issued Buy rating on June 26, 2024.
